Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,591 total articles
Medtronic (MDT) looks attractively priced after a pullback to a 52-week low, offers a 3.7% yield and strong free cash flow, and is actively deploying capital into tuck-ins. This trade idea lays out an entry at $74.00, a stop at $70.50 and a target of $86.00 over a position horizon, with clear catalysts and risks.
Halliburton is under pressure from macro swings and geopolitical noise, but the underlying business is generating cash, beating Q1 estimates and trading well below recent highs. This trade idea lays out a concrete entry, stop and target for a long trade intended to capture a recovery as oilfield activity normalizes.
Jackson Financial (JXN) offers a mix of durable annuity cashflows, a modest leverage profile, and an attractive yield. At $103.17 the stock trades below book and well under peak 2026 levels, providing a risk/reward skew favorable to patient long-term buyers. This trade outlines an entry at $103.17, a protective stop at $90.00, and a long-term targe…
Nutanix is showing signs of durable enterprise demand via longer contract durations and late-quarter revenue shifts that have created a sizable backlog. Management's increased $779M buyback and a free cash flow multiple near 17x create a tactical long opportunity. Trade plan, catalysts, risks and exit levels below.
Anthropic and other large AI customers are driving incremental high-margin spend into AWS. Amazon (AMZN) is already priced for growth but offers a favorable asymmetric trade: near-term volatility, long-term upside if AWS monetizes LLM compute. This trade idea lays out an entry, stop, target, catalysts and risks for a position lasting a few months w…
Coinbase is a leading crypto on-ramp and institutional prime-brokerage with a clean balance sheet and attractive unit economics. At about $188.61/share and a market cap near $49.7B, valuation metrics (P/E ~68.5, EV/EBITDA ~29.2, P/S ~7.3) imply meaningful growth is already priced in. This trade idea is conditional: I want to accumulate only on a de…
Auna S.A. (AUNA) trades near its 52-week low but carries a modest PE of 11.3 and a PB of 0.65. The mix of hospital operations across Peru and Colombia plus prepaid oncology plans at Oncosalud gives Auna recurring revenue characteristics that the market appears to be discounting. Technicals show oversold conditions and rising short interest; this is…
Rocket Lab ($RKLB) is trading near record highs after a string of contract wins, a robotics acquisition and accelerating revenue. The fundamentals justify interest, but sky-high valuation and negative free cash flow make this a tactical, not a buy-and-hold, idea. We outline a mid-term (45 trading days) long trade with strict risk control and a clea…
Mogotes Metals is a junior explorer working the Vicuna District with a concentrated drill program underway. The risk-reward favors a speculative long: a relatively small market footprint plus focused drilling could re-rate the stock if assays confirm broad, high-grade mineralization. The plan below defines a disciplined entry, stop, and target tied…
Circle’s operating story is moving from promise to predictable cash flows: protocol fee streams, institutional integrations and recent partner deals are starting to show up in the numbers. The market has priced growth ambitions into a high multiple, but several near-term catalysts could re-rate the stock. We outline a tactical long swing with defin…
Visa (V) combines a highly profitable payments franchise with strong free cash flow and a track record of rising payouts. At ~$330, the stock is not cheap by traditional multiples, but its 51% ROE, $21.2B in free cash flow, low net leverage and room to expand digital rails make it a pragmatic buy for long-term dividend growth. Trade plan enclosed w…
Philip Morris (PM) is trading below key short-term averages after a modest pullback. With a $273.9B market cap, $10.7B in free cash flow, an EPS of $7.11 and a ~3.2% yield, PM offers a combination of income, buyback optionality and upside from its smoke-free transition. This trade idea lays out an entry, stop and target across a clear 180 trading-d…
IonQ is showing concrete signs of moving from pure research to commercial products: record two-qubit gate fidelity, strategic manufacturing moves, and fresh government funding have re-rated the stock. Valuation is rich, volatility is high and fundamentals still show negative free cash flow, but a tactical long with defined risk controls can capture…
Mobileye combines broad OEM reach, recurring ADAS revenue and meaningful free cash flow to offer physical-AI exposure at a lower effective valuation and lower execution risk than many pure-sensor rivals. I recommend a tactical long with clearly defined entry, stop and targets over a mid-term horizon.
Sprout Social is trading well below its prior highs despite improving cash generation and a technical setup that favors a bounce. With management signaling a strong Q1 and free cash flow of roughly $46.7M, the stock looks oversold on AI-related narrative risk. This is a tactical long with a clear entry at $7.30, stop at $6.20 and a target of $12.00…
Pagaya has posted five consecutive profitable quarters, generated meaningful free cash flow and trades at modest multiples vs. growth peers. Yet about 23% of the float is short and short-volume remains high. This trade idea lays out a mid-term swing entry at $14.60 with a $20.00 target and a $12.00 stop, anchored to fundamentals, cash flow and a pl…
CACI is a core government‑services player with strong free cash flow, modest leverage, and improving technical momentum. We reaffirm Buy and lay out a clear swing trade: entry at $518.67, stop at $490, target $600 over the next 45 trading days, based on renewed federal contract wins and a favorable valuation versus growth profile.
Liberty Global (LBTYA) is trading at a steep discount to replacement-value and peers on headline multiples. With an enterprise value of roughly $10.7B against a market cap near $4.2B, EV/EBITDA around 9.4x and price/book ~0.43, the stock looks like a classic sum‑of‑the‑parts story. I put on a long trade at $12.30 with a $16.00 target and a $9.75 st…
Atea (AVIR) is a clinical-stage antiviral developer trading at a modest market cap with Phase 3 HCV programs advancing and an HEV program entering first-in-human studies. Given recent drug-drug interaction data and an improving clinical narrative, I favor a long trade into upcoming catalysts with a defined entry, stop and target — while acknowledgi…
Constellation Energy (CEG) looks like a compelling buy on a pullback: the stock is trading near the lower end of its 52-week range, the utility produces healthy free cash flow and balance-sheet metrics that can support contracts with large customers like data centers. We outline an actionable trade with entry, stop and target, plus the key risks an…
Snowflake delivered a clean earnings beat and linked a meaningful step-up in growth to AI adoption and a new $6B AWS commitment. The market has re-rated Snowflake aggressively this week, but fundamentals - 33% revenue growth, improving guidance, and $1.12B in free cash flow - argue there’s more upside. This trade idea buys the rally with a clear en…
Accelerant Holdings (ARX) has turned early momentum into measurable growth and its stock is carving a structurally bullish setup. Revenue and exchange-written premium jumped meaningfully in 2025 and technicals are confirming renewed demand. This trade idea lays out an actionable swing entry with defined stop and target, plus the key catalysts and r…
Sumitomo Corporation (SSUMY) is a classic trading-house exposure with a diversified asset base now showing signs of ROIC-friendly activity: strategic asset sales, consortium deals and a visible bid from major global allocators. At a $52.7B market cap, 13.5x P/E and a sub-2x P/B, the stock offers asymmetric upside if management uses recent monetizat…
Upstream Bio (UPB) is a clinical-stage biotech developing verekitug, a first-in-class TSLP receptor antagonist targeting severe respiratory inflammatory diseases. Recent Phase 2 data in CRSwNP and near-term regulatory interactions for Phase 3 in asthma and CRSwNP create concrete catalysts. The stock has reset from its $33.68 52-week high to about $…
Cintas (CTAS) runs a high-margin, recurring-revenue business with strong free cash flow, superior ROE, and modest leverage. The stock is trading near $173 while fundamentals and cash generation argue for upside toward $200 within the next ~45 trading days. I’m upgrading to a Buy and laying out an actionable entry, stop, and target with clear risk c…
